1-15 of 15
Mei Cheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Iron Deficiency in Young Children Beyond Anemia: Clinical Features, Maternal Factors, and the Predictor for Neuropsychomotor Development Delay

Mei-Mei Cheng, Ching-Heng Hsiao, Yen-Lin Liu, Hsi Chang, Ya-Lin Lee, Min-Lan Tsai, Wan-Ling Ho, Sung-Hui Tseng, Tefu Weng, Chia-Yau Chang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5233.
https://doi.org/10.1182/blood-2023-173129
Published: 2023
Journal Articles

Clinical Predictors and Prediction Models for Frequency of Total and Joint Hemorrhage in Severe-Type Patients with Hemophilia a (PwHA) with/without Intermediate-Dose Prophylaxis Therapy with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Jia-Ruey Tsai, Chao-Neng Cheng, Yeu-Chin Chen
Journal: Blood
Blood (2021) 138 (Supplement 1): 1047.
https://doi.org/10.1182/blood-2021-147069
Published: 2021
Journal Articles

Baseline VWF:Ag Level and Body Mass Index Are Inverse Influencing Factors of Annualized Total Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Severe-Type Adult Patients with Hemophilia a (PwHA) with Episodic Treatment with rFVIII

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Jia-Ruey Tsai, Chen-Hua Tsai, Pei-Yi Lai, Yen-Lin Liu, Chao-Neng Cheng, Yeu-Chin Chen
Journal: Blood
Blood (2021) 138 (Supplement 1): 3199.
https://doi.org/10.1182/blood-2021-150822
Published: 2021
Journal Articles

Real-World Bleeding Outcomes, Weekly Factor Consumption Doses, Annualized Factor Costs in Severe-Type Patients with Hemophilia a (PwHA) before and after Switching to Extended Half-Life rFVIII-Fc Prophylaxis

Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Pei-Yi Lai, Jung-Tzu Ku, Shu-Hsia Hu, Chen-Hua Tsai, Chao-Neng Cheng, Yen-Lin Liu, Jia-Ruey Tsai, Yeu-Chin Chen
Journal: Blood
Blood (2021) 138 (Supplement 1): 3198.
https://doi.org/10.1182/blood-2021-152066
Published: 2021
Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Jan A. Burger, Mariela Sivina, Nitin Jain, Ekaterina Kim, Tapan Kadia, Zeev Estrov, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Jeffrey Jorgensen, Jianling Li, Mei Cheng, Fong Clow, Maro Ohanian, Michael Andreeff, Thomas Mathew, Philip Thompson, Hagop Kantarjian, Susan O’Brien, William G. Wierda, Alessandra Ferrajoli, Michael J. Keating
Journal: Blood
Blood (2019) 133 (10): 1011–1019.
https://doi.org/10.1182/blood-2018-10-879429
Published: 2019
Includes: Supplemental data
Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 186.
https://doi.org/10.1182/blood-2018-99-110326
Published: 2018
Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Tadeusz Robak, MD PhD, Jan A. Burger, MD PhD, Alessandra Tedeschi, MD, Paul M. Barr, MD, Carolyn Jane Owen, MD FRCPC, Osnat Bairey, MD, Peter Hillmen, MBChB, PhD, David Simpson, MBChB, Sebastian Grosicki, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Helen McCarthy, MBBS, PhD, Steven Coutre, MD, Hang Quach, MBBS, MD, Gianluca Gaidano, MD PhD, Zvenyslava Maslyak, MD, Don A Stevens, MD, Carol Moreno, MD, Devinder Gill, MD, Ian W. Flinn, MD PhD, John Gribben, MD DSc, Ahmad Mokatrin, PhD, Mei Cheng, PhD, Lori Styles, MD, Danelle F. James, MD MAS, Thomas J. Kipps, MD, Paolo Ghia, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1750.
https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750
Published: 2017
Journal Articles

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Thomas J. Kipps, MD, PhD, Peter Hillmen, Fatih Demirkan, MD, Sebastian Grosicki, MD PhD, Steven E. Coutre, MD, Jacqueline C. Barrientos, MD, Paul M. Barr, Ann Janssens, MD, John C. Byrd, MD, Susan M. O'Brien, MD, Graeme Fraser, MD, Ulrich Jaeger, MD, Paula Cramer, MD, Stephan Stilgenbauer, MD, Asher A. Chanan-Khan, MD, Mariya Salman, PhD, Isabelle Solman, MS, Mei Cheng, PhD, Charles Phelps, MSc, Joi Ninomoto, PharmD, Angela Howes, Danelle F. James, MD MAS, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2042.
https://doi.org/10.1182/blood.V128.22.2042.2042
Published: 2016
Journal Articles

Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice

Maureen A. Shaw, Keith W. Kombrinck, Kathryn E. McElhinney, David R. Sweet, Matthew J. Flick, Joseph S. Palumbo, Mei Cheng, Naomi L. Esmon, Charles T. Esmon, Alexander Brill, Denisa D. Wagner, Jay L. Degen, Eric S. Mullins
Journal: Blood
Blood (2016) 128 (5): 721–731.
https://doi.org/10.1182/blood-2015-11-680280
Published: 2016
Includes: Multimedia, Supplemental data
Journal Articles

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

Christian Buske, Shalal Sadullah, FRCP, FRCPath, Efsthatios Kastritis, MD, Giulia Benevolo, MD, Ramon Garcia-Sanz, MD, Lukasz Bolkun, MD PhD, Xavier Leleu, MD PhD, Wolfgang Willenbacher, MD, Roman Hajek, MD, Ellen van der Spek, MD PhD, Mei Cheng, PhD, Thorsten Graef, MD PhD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2015) 126 (23): 2096.
https://doi.org/10.1182/blood.V126.23.2096.2096
Published: 2015
Journal Articles

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Peter Hillmen, MB, ChB, PhD, Graeme Fraser, MDFRCPC, Jeffrey Jones, MD MPH, Simon Rule, MD, Susan O'Brien, MD, Marie Sarah Dilhuydy, MD, Ulrich Jaeger, MD, Sebastian Grosicki, MD PhD, Florence Cymbalista, MD PhD, Steven Sun, PhD, Joi Ninomoto, PharmD, Michelle Mahler, MD, Mei Cheng, PhD, Joris Diels, Fong Clow, ScD, Mariya Salman, PhD, Danelle F. James, MD MAS, Angela Howes, PhD, Asher Chanan-Khan, MD
Journal: Blood
Blood (2015) 126 (23): 2944.
https://doi.org/10.1182/blood.V126.23.2944.2944
Published: 2015
Journal Articles

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Clinical Trials & Observations
Michael L. Wang, Kristie A. Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule
Journal: Blood
Blood (2015) 126 (6): 739–745.
https://doi.org/10.1182/blood-2015-03-635326
Published: 2015
Includes: Supplemental data
Journal Articles

Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy

Jeffrey A. Jones, MD, Peter Hillmen, MB, ChB, PhD, Steven Coutre, MD, Constantine Tam, MD, Richard R. Furman, MD, Paul M. Barr, MD, Stephen J. Schuster, MD, Thomas J. Kipps, MD, Ian W. Flinn, MD, Ulrich Jaeger, MD, Jan A. Burger, MD PhD, Mei Cheng, PhD, Dana Lee, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Susan O'Brien, MD
Journal: Blood
Blood (2014) 124 (21): 1990.
https://doi.org/10.1182/blood.V124.21.1990.1990
Published: 2014
Journal Articles

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Michael Wang, MD, Simon Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD PhD, Brad S. Kahl, MD, Wojciech Jurczak, Ranjana Advani, MD, Jorge E. Romaguera, MD, Michael E. Williams, MD, Jacqueline C. Barrientos, MD, Ewa Chmielowska, MD, John Radford, Stephan Stilgenbauer, MD, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, MD, Peter W Johnson, MD, Stephen E. Spurgeon, MD, Liang Zhang, MD PhD, Linda Baher, Mei Cheng, PhD, Darrin M. Beaupre, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2014) 124 (21): 4453.
https://doi.org/10.1182/blood.V124.21.4453.4453
Published: 2014
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Wyndham H. Wilson, MD, PhD, John F. Gerecitano, MD, PhD, Andre Goy, MD, Sven de Vos, MD, PhD, Vaishalee P. Kenkre, MD, Paul M. Barr, MD, Kristie A. Blum, MD, Andrei R. Shustov, MD, Ranjana H. Advani, MD, Jason Lih, PhD, Mickey Williams, PhD, Roland Schmitz, PhD, Yandan Yang, PhD, Stefania Pittaluga, MD, PhD, George Wright, PhD, Lori A. Kunkel, MD, Jesse McGreivy, MD, Sriram Balasubramanian, PhD, Mei Cheng, PhD, Davina Moussa, Joseph J. Buggy, PhD, Louis M. Staudt, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 686.
https://doi.org/10.1182/blood.V120.21.686.686
Published: 2012